DENVER, July 8, 2010 (GLOBE NEWSWIRE) -- Dyer & Berens LLP (www.DyerBerens.com) announced today that it is continuing its investigation concerning losses suffered by certain XenoPort, Inc. investors (Nasdaq:XNPT).
The law firm's investigation concerns whether XenoPort released misleading and/or incomplete information about its clinical trial program for gabapentin enacarbil as a treatment for Restless Leg Syndrome, including that there was strong evidence of safety and indicating that it remained on track. After the FDA denied approval of gabapentin enacarbil due to concerns about laboratory results showing pancreatic cell tumors in rats, XenoPort's stock price tumbled 60% to $6.67 per share on February 18, 2010.
If you purchased XenoPort common stock prior to February 18, 2010 or if you have information relevant to the investigation, you may contact Jeffrey A. Berens, Esq. at (888) 300-3362 x302, (303) 861-1764 or via email at jeff@dyerberens.com.
The law firm of Dyer & Berens LLP focuses on complex litigation on behalf of injured investors throughout the nation. For more information about the firm, please go to www.DyerBerens.com.